Next Generation Pharmaceutical Asia

Asia's generic market has blossomed in recent years, but could changes in patent and exclusivity laws put the brakes on this growth? In this issue, we examine how recent changes to Asian pharma's legal landscape could turn the tide on generics producers and their likely response.

Conversely, how can the pharmaceuticals companies survive the threat from their generic competitors and recoup some of the vast sums of money they invest in product development? Perhaps bioinformatics are one answer, bringing greater efficiency, accuracy, transparency and cost savings to an industry that must now look to streamline operations?

In this issue

Browse Featured Companies